Drug Profile
Research programme: synthetic peptide therapeutics - GeoPharma
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Florida
- Developer GeoPharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pulmonary-hypertension in USA
- 25 Aug 2009 This programme is in active development
- 31 Jan 2006 Preclinical trials in Pulmonary hypertension in USA (unspecified route)